6,7-二氢-5H环戊[b]并吡啶-2-醇 | 88499-85-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6,7-二氢-5H环戊[b]并吡啶-2-醇
• 中文别名: 1,5,6,7-四氢-2H-环戊并[b]吡啶-2-酮
• 英文名称: 1,5,6,7-tetrahydro-2H-cyclopentan[b]pyridin-2-one
• 英文别名: 1,5,6,7-tetrahydro-2H-cyclopenta[b]pyridin-2-one；6,7-dihydro-1H-cyclopenta[b]pyridin-2(5H)-one；cyclopentanopyridone-2；2-Oxo-1,2-dihydro-cyclopentanopyridin；2-Oxo-1,2-dihydro-cyclopentano[e]pyridin；6,7-Dihydro-5h-cyclopenta[b]pyridin-2-ol；1,5,6,7-tetrahydrocyclopenta[b]pyridin-2-one
• CAS: 88499-85-8
• 化学式: C₈H₉NO
• mdl: MFCD09040473
• 分子量: 135.166
• InChiKey: GXXRRIYKTZNCNC-UHFFFAOYSA-N

物化性质

• 熔点：
  180-181 °C(Solv: water (7732-18-5))
• 沸点：
  402.7±18.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,5,6,7-Tetrahydro-2H-cyclopenta[b]pyridin-2-one
Synonyms: 1H,5H,6H,7H-Cyclopenta[b]pyridin-2-one

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,5,6,7-Tetrahydro-2H-cyclopenta[b]pyridin-2-one
CAS number: 88499-85-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9NO
Molecular weight: 135.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6,7-二氢-5H环戊[b]并吡啶-2-醇 在 镍 盐酸 、 manganese(IV) oxide 、 正丁基锂 、 四甲基乙二胺 、 硫酸 、 苄基三乙基氯化铵 、 氢气 、 硝酸 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 80.0 ℃ 、202.65 kPa 条件下， 反应 28.0h， 生成 3-Amino-4-(3-methylbenzoyl)-1,5,6,7-tetrahydrocyclopenta[b]pyridin-2-one
  参考文献：
  名称：

  4-Benzyl and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones:  In Vitro Evaluation of New C-3-Amino-Substituted and C-5,6-Alkyl-Substituted Analogues against Clinically Important HIV Mutant Strains

  摘要：

  In a program to optimize the anti-HIV activity of the 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 9 and 10, lead compounds in a new class of highly potent non-nucleoside type inhibitors of HIV-1 reverse transcriptase, modification of the alkyl substitutents at the C-5 and C-6 positions on the pyridinone ring and of the substitutents on the C-3 amino group has been studied. Of the 17 new 5/6-modified analogues prepared, compounds 31b and 32b substituted at C-5 by an extended nonpolar chain containing an ether function and a C-6 methyl group and compound 35 bearing a C-5 ethyl/C-6 hydroxymethyl substituent pattern were selected on the basis of their in vitro activity against wild-type HIV and the three principle mutant strains, K103N, Y181C, and Y188L. When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L1001 + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A] which are clinically relevant. Concerning modulation of the N-3 substituent, 36 new analogues were prepared. Of these, the N-methyl-N-(2-methoxyethyl)-substituted compounds 40, 42, and 62, as well as the doubly modified compounds 77a and 77b, were selected from the initial screen and were subsequently shown to be active at sub-micromolar concentrations (IC50'S) against all the other mutant strains except K103N + Y181C and F227L + V106A. Two possible, but distinct, modes of binding of these analogues in RT were suggested from molecular modeling studies. The preferred mode of binding for compound 62, corresponding to the predicted "orientation 1", was revealed in the X-ray crystal structure of the compound 62-RT complex.

  DOI：

  10.1021/jm0408621
• 作为产物：
  描述：

  3-(2-氧代环戊基)丙腈 在 溴 、 溶剂黄146 作用下， 以60%的产率得到6,7-二氢-5H环戊[b]并吡啶-2-醇
  参考文献：
  名称：

  无需安装外来指导基团的α-氨基酸的配体激活β-C-H芳基化

  摘要：

  在本文中，我们报道了吡啶型配体使α-氨基酸的酸导向β-C（sp 3）-H芳基化反应。该反应不需要安装外源性指导基团，具有可扩展性，并且可以通过三个步骤制备受Fmoc保护的非天然氨基酸。吡啶型配体对于这种新的C（sp 3）-H芳基化的发展至关重要。

  DOI：

  10.1002/anie.201610580

文献信息

• 一种制备含吡啶并环戊烷手性氮磷配体L-8的方法
  申请人：南京艾普特生物医药有限公司

  公开号：CN112521419A

  公开（公告）日：2021-03-19

  本发明公开了制备含吡啶并环戊烷手性氮磷配体L‑8的方法，属于医药中间体手性配体技术领域。从环戊酮出发，依次经过加成、环合、氯代、不对称硼化、氧化、偶联、成酯等步骤后完成得到手性氮磷L‑8配体该路线相对比较容易实现较大规模的制备，克服了传统路线中第一步关环反应和手性醇制备时收率低，通过选择合适的手性配体，与丁基锂结合，实现了不对称合成手性醇，避免了文献中采用手性分离柱方式。
• 一种合成含吡啶并环庚烷手性氮磷配体L-8的方法
  申请人：南京艾普特生物医药有限公司

  公开号：CN112521420A

  公开（公告）日：2021-03-19

  本发明公开了合成含吡啶并环庚烷手性氮磷配体L‑8的方法，属于医药中间体手性配体技术领域。从环戊酮出发，依次经过加成、环合、氯代、不对称硼化、氧化、偶联、成酯等步骤后完成得到手性氮磷L‑8配体该路线相对比较容易实现较大规模的制备，克服了传统路线中第一步关环反应和手性醇制备时收率低，通过选择合适的手性配体，与丁基锂结合，实现了不对称合成手性醇，避免了文献中采用手性分离柱方式。
• ANTI-FIBROTIC PYRIDINONES
  申请人：InterMune, Inc.

  公开号：US20140094456A1

  公开（公告）日：2014-04-03

  Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

  揭示了吡啶酮化合物，制备这些化合物的方法，以及治疗纤维化疾病的方法。
• [EN] 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES D'ÉTHER D'HÉTÉROARYLE PIPÉRIDINE 6,5-FUSIONNÉS DU RÉCEPTEUR MUSCARINIQUE DE L'ACÉTYLCHOLINE M4
  申请人：MERCK SHARP & DOHME

  公开号：WO2018118736A1

  公开（公告）日：2018-06-28

  The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及6,5-融合杂环哌啶醚化合物，这些化合物是M4肌氨酸乙酰胆碱受体的变构调节剂。本发明还涉及所述化合物在潜在的治疗或预防神经系统和精神疾病中的用途，这些疾病和疾病中涉及M4肌氨酸乙酰胆碱受体。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及M4肌氨酸乙酰胆碱受体的疾病中的用途。
• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2016202898A1

  公开（公告）日：2016-12-22

  The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及选择性抑制葡萄糖转运蛋白1（GLUT1）的化合物，涉及制备该类化合物的方法，涉及包含该类化合物的药物组合物和药物组合物，涉及利用该类化合物制造用于治疗或预防疾病的药物组合物，以及用于制备该类化合物的中间化合物。